Fuse Vectors develops cell-free technology to manufacture Adeno-Associated Virus (AAV) vectors for gene therapy applications. Their enzymatic system replaces traditional cell-based processes, enabling the production of high-quality AAVs with superior purity and consistency in a single step. This platform accelerates the development and scalability of potent gene therapy treatments for patients.
Funding
$580K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BIFounders
Product
Problem
Traditional cell-based methods for manufacturing adeno-associated viral vectors (AAVs) suffer from inefficiencies, leading to low therapeutic efficacy, high toxicity, slow development cycles, and costly production. These challenges hinder the widespread accessibility and development of gene therapies.
Solution
Fuse Vectors utilizes a cell-free AAV filling platform, called Fuse Technology, to manufacture AAVs. This technology eliminates the need for traditional cell-based processes, ensuring high purity of the AAV product in a single step. By creating AAVs outside of cells, Fuse Vectors aims to overcome the limitations of current AAV production methods, incentivizing gene therapy development and accelerating the creation of safer and more effective therapies. The combination of Fuse Technology and an optimization engine seeks to lower barriers to entry into AAV production for all gene therapy developers.
Target Audience
The primary target audience includes gene therapy developers seeking to overcome the limitations of traditional AAV production methods and accelerate the development of novel therapies.
Features
- Cell-free AAV filling platform eliminating cell-based processes.
- Single-step production ensuring high purity of AAV product.
- Scalable technology suitable for complex AAV development and production.
- Optimization engine to enhance gene therapy development.